MegaPro Biomedical

Hsinchu, Taiwan Founded: 2014 • Age: 12 yrs Listed
Developer of niche-type nano-drugs for cancer

About MegaPro Biomedical

MegaPro Biomedical is a publicly listed company based in Hsinchu (Taiwan) founded in 2014. Developer of niche-type nano-drugs for cancer. It operates in the Healthcare and Technology sectors. The company has 27 employees. Its chief executive, as recorded, is Jassy Wang. Its focus areas include Life Sciences, Hematology, Drugs and Diversified.

Company details

MegaPro Biomedical was founded in 2014 in Hsinchu, Taiwan, within the biotechnology sector. Proprietary PEGylated iron oxide nanoparticles, branded as IOP Injection, are developed as a contrast agent for magnetic resonance imaging. Additionally, this non-sugar-based intravenous iron formulation is targeted for iron-deficiency anemia and hepatocellular carcinoma treatments. Operations center on advancing these niche pharmaceutical applications through research and development.

  • Headquarters Hsinchu, Taiwan
  • Employees 27
  • Stage Public
  • Sectors
    Healthcare
    Technology
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website megaprobio.com
  • Legal Name Megapro Biomedical Co., Ltd.
Key Metrics
  • Net Profit
    -$119.1 M
    27.39
    as on Dec 31, 2025
  • EBITDA
    -$104.53 M
    35.86
    as on Dec 31, 2025
  • Employee Count
    27

People of MegaPro Biomedical

1 people are tracked at MegaPro Biomedical (1 in leadership); the tracked headcount is 27.

NameRoleGroup
Jassy Wang
CEOLeadership
Premium access

Complete people profiles for MegaPro Biomedical

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of MegaPro Biomedical

MegaPro Biomedical is a publicly listed company on the TPEX with ticker symbol 6827 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date19 Oct 2021
  • Listed onTT: 6827
  • Listed entityMegaPro Biomedical Co., Ltd.
  • Exchange sectorHealth technology
  • ISINTW0006827009
  • Share price13.65 TWD (+0.37% on the day) · 2026-10-14
  • Market capitalisation1,069,085,250.00 TWD
  • EPS (diluted, trailing year)-1.29 TWD
  • Volume (last session)641,441

Financials of MegaPro Biomedical

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025-119.1M TWD-104.5M TWD
202414,000 TWD-164.0M TWD-163.0M TWD
202318,000 TWD-127.5M TWD-123.9M TWD
2022-111.7M TWD-108.2M TWD
2021-89.2M TWD-93.4M TWD
Premium access

Detailed financial statements for MegaPro Biomedical

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about MegaPro Biomedical

MegaPro Biomedical was founded in 2014.

MegaPro Biomedical is headquartered in Hsinchu, Taiwan.

Jassy Wang is the CEO of MegaPro Biomedical, as recorded in our data.

MegaPro Biomedical has 27 employees.

MegaPro Biomedical was founded in 2014 in Hsinchu, Taiwan, within the biotechnology sector. Proprietary PEGylated iron oxide nanoparticles, branded as IOP Injection, are developed as a contrast agent for magnetic resonance imaging. Additionally, this non-sugar-based intravenous iron formulation is targeted for iron-deficiency anemia and hepatocellular carcinoma treatments. Operations center on advancing these niche pharmaceutical applications through research and development.

Yes, MegaPro Biomedical is publicly traded on TPEX under the ticker symbol 6827.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available